Get the Stockscreener App
3.2885
6.86%
-0.2415
Checkpoint Therapeutics Inc stock is traded at $3.2885, with a volume of 547.01K.
It is down -6.86% in the last 24 hours and down -4.42% over the past month.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
See More
Previous Close:
$3.53
Open:
$3.51
24h Volume:
547.01K
Relative Volume:
0.42
Market Cap:
$172.38M
Revenue:
$103.00K
Net Income/Loss:
$-42.47M
P/E Ratio:
-1.7308
EPS:
-1.9
Net Cash Flow:
$-34.30M
1W Performance:
+15.77%
1M Performance:
-4.42%
6M Performance:
+48.10%
1Y Performance:
+70.35%
1-Day Range:
$3.265
$3.56
1-Week Range:
$2.77
$3.86
52-Week Range:
$1.38
$4.50
Checkpoint Therapeutics Inc Stock (CKPT) Company Profile
Name
Checkpoint Therapeutics Inc
Sector
Industry
Phone
781-652-4500
Address
95 SAWYER ROAD, WALTHAM, NY
Compare CKPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CKPT
Checkpoint Therapeutics Inc
|
3.2889 | 172.38M | 103.00K | -42.47M | -34.30M | -1.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.85 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.27 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.13 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.65 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.63 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Checkpoint Therapeutics Inc Stock (CKPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-25 | Initiated | D. Boral Capital | Buy |
| Jul-14-22 | Resumed | B. Riley Securities | Buy |
| Jun-09-21 | Initiated | B. Riley Securities | Buy |
| Jan-20-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-29-19 | Initiated | Lake Street | Buy |
| Dec-08-17 | Initiated | H.C. Wainwright | Buy |
View All
Checkpoint Therapeutics Inc Stock (CKPT) Latest News
The time has not yet come to remove your chips from the table: Checkpoint Therapeutics Inc (CKPT) - SETE News
Analyzing Ratios: Checkpoint Therapeutics Inc (CKPT)’s Financial Story Unveiled - The Dwinnex
Technical analysis of Checkpoint Therapeutics Inc (CKPT) stock chart patterns - US Post News
Checking in on Checkpoint Therapeutics Inc (CKPT) after recent insiders movement - Knox Daily
Checkpoint Therapeutics Inc (CKPT) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Checkpoint Therapeutics (CKPT) Stock Price, News & Analysis - MarketBeat
Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) Profit Outlook - Simply Wall St
Short Interest in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Increases By 17.5% - MarketBeat
Reviewing LifeVantage (NASDAQ:LFVN) & Checkpoint Therapeutics (NASDAQ:CKPT) - Defense World
Checkpoint Therapeutics (NASDAQ:CKPT) Coverage Initiated by Analysts at D. Boral Capital - Defense World
Checkpoint Therapeutics stock initiated at Buy Rating by Borak Capital - Investing.com Canada
This PG&E Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
D. Boral Capital Initiates Coverage on Checkpoint Therapeutics (NASDAQ:CKPT) - MarketBeat
Checkpoint Therapeutics CFO signs new executive agreement By Investing.com - Investing.com Australia
Checkpoint Therapeutics CFO signs new executive agreement - Investing.com India
Geode Capital Management LLC Buys 124,787 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) - Defense World
Checkpoint Therapeutics Signs Executive Agreement with CFO - TipRanks
Fortress Biotech subsidiary's drug application accepted by FDA - Investing.com Australia
Checkpoint Therapeutics Inc (NASDAQ: CKPT) Today’s Hot Stock - Stocks Register
State Street Corp Grows Stock Holdings in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) - Defense World
Head to Head Contrast: Tyra Biosciences (NASDAQ:TYRA) and Checkpoint Therapeutics (NASDAQ:CKPT) - Defense World
Checkpoint Therapeutics CFO sells $1.08 million in stock - Investing.com India
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO Sells 268,432 Shares - MarketBeat
James F. Oliviero III Sells 220,230 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Stock - MarketBeat
Checkpoint Therapeutics CFO sells $1.08 million in stock By Investing.com - Investing.com Canada
Checkpoint Therapeutics CEO sells $3.07 million in stock By Investing.com - Investing.com Canada
Checkpoint Therapeutics: Updating My Strategy After Unloxcyt's Approval (NASDAQ:CKPT) - Seeking Alpha
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT for Treatment of Advanced Cutaneous Squamous Cell Carcinoma - Defense World
Affimed Shares Fall 32% on Clinical Update - Yahoo Finance
Fortress Biotech subsidiary gains FDA approval for cSCC therapy - Investing.com
Soligenix initiates confirmatory Phase 3 trial of HyBryte - Yahoo Finance
Checkpoint Therapeutics (NASDAQ:CKPT) Receives Buy Rating from HC Wainwright - Defense World
Checkpoint Therapeutics (NASDAQ:CKPT) Price Target Raised to $7.00 at Lake Street Capital - Defense World
FDA Tracker: Neurocrine, Checkpoint Score FDA Approvals - BioSpace
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Short Interest Up 9.0% in November - MarketBeat
Investors Purchase Large Volume of Call Options on Checkpoint Therapeutics (NASDAQ:CKPT) - MarketBeat
FDA Approves Cosibelimab for Cutaneous SCC - Medscape
Checkpoint Therapeutics (NASDAQ:CKPT) Price Target Raised to $7.00 - MarketBeat
FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for Checkpoint Therapeutics (NASDAQ:CKPT) - MarketBeat
US Stocks To Open Higher Ahead Of Fed's Decision This Week: Analyst Says 'Santa Comes Later In December' - Benzinga
FDA approves Checkpoint Thera’s Unloxcyt - The Pharma Letter
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Checkpoint stock on watch after FDA nod (CKPT:NASDAQ) - Seeking Alpha
Checkpoint Therapeutics' Shares Rise After Securing First FDA Approval - Marketscreener.com
Checkpoint Therapeutics Gets Its First FDA Approval - Marketscreener.com
US FDA approves Checkpoint's skin cancer drug - Reuters.com
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - GlobeNewswire
Checkpoint Therapeutics Inc Stock (CKPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Checkpoint Therapeutics Inc Stock (CKPT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Oliviero James F III | CEO, President and Director |
Dec 19 '24 |
Sale |
3.38 |
220,230 |
744,377 |
3,194,583 |
| GRAY WILLIAM GARRETT | Chief Financial Officer |
Dec 18 '24 |
Sale |
4.01 |
268,432 |
1,076,412 |
1,032,754 |
| Oliviero James F III | CEO, President and Director |
Jun 26 '24 |
Sale |
2.05 |
24,610 |
50,450 |
1,977,170 |
| GRAY WILLIAM GARRETT | Chief Financial Officer |
Jun 26 '24 |
Sale |
2.06 |
13,038 |
26,858 |
672,186 |
| Oliviero James F III | CEO, President and Director |
Feb 28 '24 |
Sale |
2.06 |
5,894 |
12,142 |
350,836 |
| GRAY WILLIAM GARRETT | Chief Financial Officer |
Feb 28 '24 |
Sale |
2.07 |
2,035 |
4,212 |
145,224 |
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):